|Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.|
|PMID: 23406976 Owner: NLM Status: MEDLINE|
|BACKGROUND: Mechanisms for increased cardiovascular risk in HIV-1-infected adults are incompletely understood, but platelet activation and immune activation leading to a prothrombotic state have been proposed as significant contributors. Aspirin has antiplatelet and immunomodulatory properties. We explored whether 1 week of low-dose aspirin attenuates platelet activation and immune activation in HIV-1-infected and virologically suppressed adults on antiretroviral therapy.
METHODS: Platelet activation and immune activation were measured in HIV-1-infected subjects virologically suppressed on antiretroviral therapy and controls before and after 1 week of low-dose aspirin.
RESULTS: Compared with control subjects, HIV-1-infected subjects had increased platelet activation, as measured by spontaneous platelet aggregation and aggregation in response to adenosine diphosphate, collagen, and arachidonic acid. After aspirin therapy, percent aggregation decreased similarly in both HIV-1-infected and control subjects to all platelet agonists tested except aggregation in response to arachidonic acid, which remained elevated in the HIV-1-infected group. HIV-1-infected subjects exhibited increased markers of T-cell activation (CD38 and HLA-DR) and monocyte activation (sCD14), which decreased after 1 week of aspirin therapy. Moreover, leukocyte responses to Toll-like receptor stimulation were enhanced after 1 week of aspirin therapy. In vitro studies showed that HIV-1 plasma could activate healthy platelets, which in turn activated monocytes, implicating a direct role for activated platelets in immune activation.
CONCLUSIONS: Our data demonstrate that heightened platelet activation and immune activation in treated HIV-1 disease are attenuated by 1 week of aspirin therapy. Aspirin should be further studied for its antithrombotic and immunomodulatory benefits in treated HIV-1 disease.
|Meagan O'Brien; Emilie Montenont; Liang Hu; Michael A Nardi; Vanessa Valdes; Michael Merolla; Gabrielle Gettenberg; Karen Cavanagh; Judith A Aberg; Nina Bhardwaj; Jeffrey S Berger|
Related Documents :
|23715106 - Heparin-induced thrombocytopenia associated with thrombotic microangiopathy.
10378836 - White cell reduction during plateletpheresis: a comparison of three blood cell separators.
25418726 - Scalable generation of universal platelets from human induced pluripotent stem cells.
22431576 - Advanced glycation end products induce a prothrombotic phenotype in mice via interactio...
20198486 - May platelet count be a predictor of low-risk persistent gestational trophoblastic dise...
2960196 - Effect of ginkgolide paf-acether antagonists on arterial thrombosis.
|Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't|
|Title: Journal of acquired immune deficiency syndromes (1999) Volume: 63 ISSN: 1944-7884 ISO Abbreviation: J. Acquir. Immune Defic. Syndr. Publication Date: 2013 Jul|
|Created Date: 2013-06-13 Completed Date: 2013-08-29 Revised Date: 2014-07-02|
Medline Journal Info:
|Nlm Unique ID: 100892005 Medline TA: J Acquir Immune Defic Syndr Country: United States|
|Languages: eng Pagination: 280-8 Citation Subset: IM; X|
|APA/MLA Format Download EndNote Download BibTex|
Anti-HIV Agents / therapeutic use
Arachidonic Acid / pharmacology
Aspirin / pharmacology, therapeutic use*
Collagen / pharmacology
HIV Infections / blood*, drug therapy, immunology*
HIV-1* / drug effects
Inflammation / drug therapy
Lymphocyte Activation / drug effects*
P-Selectin / blood
Platelet Activation / drug effects*
Platelet Aggregation / drug effects
Platelet Aggregation Inhibitors / pharmacology, therapeutic use
Platelet Function Tests
Thromboxanes / urine
|5 U01 AI069532/AI/NIAID NIH HHS; K08 AI093153/AI/NIAID NIH HHS; P30 AI027742/AI/NIAID NIH HHS; UL1 TR000038/TR/NCATS NIH HHS; UM1 AI069532/AI/NIAID NIH HHS|
|0/Anti-HIV Agents; 0/P-Selectin; 0/Platelet Aggregation Inhibitors; 0/Thromboxanes; 27YG812J1I/Arachidonic Acid; 61D2G4IYVH/Adenosine Diphosphate; 9007-34-5/Collagen; R16CO5Y76E/Aspirin|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The clinical significance of calcium-signalling pathways mediating human sperm hyperactivation.
Next Document: Evaluation of using Routine Infant Immunization Visits to Identify and Follow-up HIV-exposed Infants...